このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

成人眼筋無力症患者におけるロザノリキシマブの長期安全性および有効性を評価する研究 (MyVisionXT)

2026年11月5日 更新者:UCB Biopharma SRL

眼筋無力症の成人参加者におけるRozanolixizumabの長期安全性および有効性を評価するための第3相オープンラベル延長試験

The purpose of the study is to assess the long-term safety and efficacy of rozanolixizumab in adult study participants with ocular myasthenia gravis.

調査の概要

状態

募集

介入・治療

研究の種類

介入

入学 (推定)

100

段階

  • フェーズ 3

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究連絡先のバックアップ

  • 名前:UCB Cares
  • 電話番号:00184459922733 (UCB)
  • メール:ucbcares@ucb.com

研究場所

    • Arizona
      • Scottsdale、Arizona、アメリカ、85251
        • 募集
        • Mg0039 10104
    • Ohio
      • Columbus、Ohio、アメリカ、43210
        • 募集
        • Mg0039 10103
      • Sarajishvili、グルジア
        • 募集
        • Mg0039 21403
      • Tbilisi、グルジア
        • 募集
        • Mg0039 21402
      • Barcelona、スペイン
        • 募集
        • Mg0039 20604
      • Madrid、スペイン
        • 募集
        • Mg0039 20611
      • Murcia、スペイン
        • 募集
        • Mg0039 20602
      • Málaga、スペイン
        • 募集
        • Mg0039 20606
      • Nice、フランス
        • 募集
        • Mg0039 20301
      • Lublin、ポーランド
        • 募集
        • Mg0039 21206
      • Beijing、中国
        • 募集
        • Mg0039 31901
      • Beijing、中国
        • 募集
        • Mg0039 31912
      • Chongqing、中国
        • 募集
        • Mg0039 31908
      • Nanchang、中国
        • 募集
        • Mg0039 31907
      • Suzhou、中国
        • 募集
        • Mg0039 31902
      • Kobe、日本
        • 募集
        • Mg0039 31802
      • Minatoku、日本
        • 募集
        • Mg0039 31804
      • Sendai、日本
        • 募集
        • Mg0039 31805

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Participant must be a minimum of 18 years of age inclusive at the time of signing the informed consent form (ICF)

  • Participant must have received at least 1 dose of investigational medicinal product (IMP) (rozanolixizumab or placebo) in MG0038

  • Participant for whom the investigator considers a favorable benefit/risk for participation

  • Participant who, alone or with assistance of the caregiver, is considered reliable and capable of adhering to the protocol visit schedule or medication intake according to the judgement of the investigator

  • Male or female

  • A female participant is eligible to participate if she is not, not breastfeeding (including pumping breastmilk to feed a child), and at least 1 of the following conditions applies:

    • Not a woman of childbearing potential (WOCBP) OR
    • A WOCBP who agrees to follow the contraceptive guidance for the entire study period
  • Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the ICF and in the protocol

Exclusion Criteria:

  • Participant meets any of the withdrawal criteria defined in MG0038
  • Participant has a clinically relevant active infection (resulting in hospitalization or requiring intravenous (IV) antibiotic treatment) within 6 weeks before study entry.
  • Participant intends to have a live vaccination during the study or within 8 weeks following the final dose of rozanolixizumab
  • Participant has been administered with the prohibited immunosuppressive medications, biologics, or other therapies
  • Participant has planned use of prohibited medications

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:なし
  • 介入モデル:単一グループの割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Rozanolixizumab

The study is composed of Extended Observation Period(s) and Symptom-driven Cycle(s). Based on their clinical need for treatment, study participants will be able to start the study with either an Extended Observation Period or a Symptom-driven Cycle.

A Symptom-driven Cycle will be initiated based on disease worsening and participants will receive rozanolixizumab based on investigator's medical judgement.

Rozanolixizumab will be administered by subcutaneous infusion.

他の名前:
  • UCB7665

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Incidence of treatment-emergent adverse events (TEAEs)
時間枠:Up to 2 years

Treatment Emergent Adverse Events (TEAEs) are any untoward medical incidence in a participant after the administration of study treatment, whether or not these events are related to study treatment.

Up to 2 years
Incidence of treatment-emergent serious adverse events (TESAEs)
時間枠:Up to 2 years

An SAE is defined as any untoward medical occurrence that, at any dose, meets 1 or more of the criteria listed:

  • Results in death
  • Is life-threatening
  • Requires inpatient hospitalization or prolongation of existing hospitalization
  • Results in persistent or significant disability/incapacity
  • Is a congenital anomaly/birth defect
  • Other important medical events which based on medical or scientific judgement may jeopardize the patients or may require medical or surgical intervention to prevent any of the above.
Up to 2 years
Incidence of TEAEs leading to permanent withdrawal of study treatment
時間枠:Up to 2 years

Treatment Emergent Adverse Events (TEAEs) are any untoward medical incidence in a participant after the administration of study treatment, whether or not these events are related to study treatment. This measure considers any TEAE leading to permanent withdrawal from study.

Up to 2 years

二次結果の測定

結果測定
メジャーの説明
時間枠
Change from Baseline at Day 43 in (Myasthenia Gravis Impairment Index) MGII ocular score (Patient-Reported Outcome part)
時間枠:At Day 43 (of the first 3 Symptom-driven Cycles)

MGII is a measure of disease severity based on the signs and symptoms of MG patients. The MGII has 22 patient-reported items and 6 examination items and scores are presented as a sum of all items for a total score but also as an ocular and generalized sub-score. The scoring range is 0 to 84, 0-23 for the ocular score, and 0-61 for the generalized score, where higher scores are indicative of more severe symptoms. The recall period is "the past week".

At Day 43 (of the first 3 Symptom-driven Cycles)
Change from Baseline at Day 43 in Myasthenia Gravis Activities of Daily Living (MG-ADL) ocular score
時間枠:At Day 43 (of the first 3 Symptom-driven Cycles)

The MG-ADL score is an 8-item patient-reported outcome (PRO) instrument. The MG-ADL targets symptoms and disability across ocular, bulbar, respiratory, and axial symptoms. The item responses are scored from 0 to 3, and the total score of MG-ADL is the sum of the 8 items and ranges from 0 to 24, with a higher score indicating more disability. The two ocular items will be summed for the ocular score, ranging from 0 to 6.

At Day 43 (of the first 3 Symptom-driven Cycles)
Change from Baseline at Day 43 in Myasthenia Gravis Symptoms Patient-Reported Outcome (MGSPRO) ocular muscle weakness scale score
時間枠:At Day 43 (of the first 3 Symptom-driven Cycles)

The MG symptoms PRO instrument consisted of 42 items across 5 scales: ocular muscle weakness (items 1-5); bulbar muscle weakness (items 6-15); respiratory muscle weakness (items 16-18); physical fatigue (items 19-33) and muscle weakness fatigability (items 34-42). Only the ocular muscle weakness scale will be used in this study. Ocular symptom severity is assessed over the past 7 days using a 4-point verbal rating scale (none, mild, moderate, severe)

At Day 43 (of the first 3 Symptom-driven Cycles)
Change from Baseline at Day 43 in Myasthenia Gravis Quality of Life 15-item Scale (revised version) (MG-QoL15r) total score
時間枠:At Day 43 (of the first 3 Symptom-driven Cycles)

The MG-QoL15r is a 15-item PRO measure that is designed to assess aspects of health-related quality of life related to MG. The recall period that will be used is "past 7 days". Each item has 3 response options (0-2) and the total score ranges from 0 to 30, with higher scores indicating more severe impact on health-related QoL (HRQOL).

At Day 43 (of the first 3 Symptom-driven Cycles)
Study participant who generalizes to Myasthenia Gravis Foundation of America (MGFA) class ≥2 over time
時間枠:Up to 2 years

MGFA Clinical Classification is a 5-stage classification (I to V), with a higher class indicating more severe disease.

Up to 2 years
Change from Baseline in MGII total and generalized score over time
時間枠:Up to 2 years

MGII is a measure of disease severity based on the signs and symptoms of MG patients. The MGII has 22 patient-reported items and 6 examination items and scores are presented as a sum of all items for a total score but also as an ocular and generalized sub-score. The scoring range is 0 to 84, 0-23 for the ocular score, and 0-61 for the generalized score, where higher scores are indicative of more severe symptoms. The recall period is "the past week".

Up to 2 years
Change from Baseline in MG-ADL total score over time
時間枠:Up to 2 years

The MG-ADL score is an 8-item patient-reported outcome (PRO) instrument. The MG-ADL targets symptoms and disability across ocular, bulbar, respiratory, and axial symptoms. The item responses are scored from 0 to 3, and the total score of MG-ADL is the sum of the 8 items and ranges from 0 to 24, with a higher score indicating more disability. The two ocular items will be summed for the ocular score, ranging from 0 to 6.

Up to 2 years

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2026年9月16日

一次修了 (推定)

2031年3月17日

研究の完了 (推定)

2031年3月17日

試験登録日

最初に提出

2026年3月6日

QC基準を満たした最初の提出物

2026年3月6日

最初の投稿 (実際)

2026年3月11日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月6日

QC基準を満たした最後の更新が送信されました

2026年11月5日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • MG0039
  • 2025-524757-14-00 (Ctis)
  • U1111-1334-3218 (その他の識別子:Universal Trial Number)
  • CTR20262521 (レジストリ識別子:ChinaDrugTrials.org.cn)
  • 2025 (米国 NIH グラント/契約)

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient-level data and redacted trial documents which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal. This plan may change if the risk of re-identifying trial participants is determined to be too high after the trial is completed; in this case and to protect participants, individual patient-level data would not be made available.

IPD 共有時間枠

Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.

IPD 共有アクセス基準

Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.

IPD 共有サポート情報タイプ

  • STUDY_PROTOCOL
  • SAP
  • CSR

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する